Concentrations of nanoparticle composites were selected based on their EC10 characteristics and confirmed using a Cytotoxicity LDH Test (Roche, Warsaw, Poland), according to the manufacturer’s protocols. Cell viability was determined by a Crystal Violet Assay (Sigma-Aldrich, St. Louis, MO, USA).
Cytotoxicity ldh test
Manufactured by Roche
Sourced in Poland
The Cytotoxicity LDH Test is a laboratory assay used to measure the release of lactate dehydrogenase (LDH) from cells. LDH is an enzyme present in the cytoplasm of cells and is released upon cell death or damage. The test quantifies the amount of LDH released, which is proportional to the number of damaged or lysed cells, providing a measure of cytotoxicity or cell viability.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using cytotoxicity ldh test
1
Cytotoxicity Screening of Nanoparticle Composites
2
Investigating CLA Isomers and PPAR Agonists
Check if the same lab product or an alternative is used in the 5 most similar protocols
cis9,trans11CLA and trans10,cis12CLA isomers (Nu-Chek Prep, USA) were dissolved in ethanol and stored under nitrogen in −20°C and were introduced to cell cultures at final concentrations corresponding to their concentration in CLA-enriched egg yolk: cis9,trans11 at 30 μM and trans10,cis12 at 12 μM.
The synthetic agonists and antagonists for PPARα (WY14643 and GW-6471), PPARδ (GW-0742 and GSK0660), and PPARγ (pioglitazone (PIO), troglitazone, and T0070907) were prepared as per appropriate protocols of the manufacturer. Respective concentrations were selected based on their EC/IC50 characteristics and confirmed for MCF-7 cell line using Cytotoxicity LDH Test (Roche, Poland).
+ Expand
cis9,trans11CLA and trans10,cis12CLA isomers (Nu-Chek Prep, USA) were dissolved in ethanol and stored under nitrogen in −20°C and were introduced to cell cultures at final concentrations corresponding to their concentration in CLA-enriched egg yolk: cis9,trans11 at 30 μM and trans10,cis12 at 12 μM.
The synthetic agonists and antagonists for PPARα (WY14643 and GW-6471), PPARδ (GW-0742 and GSK0660), and PPARγ (pioglitazone (PIO), troglitazone, and T0070907) were prepared as per appropriate protocols of the manufacturer. Respective concentrations were selected based on their EC/IC50 characteristics and confirmed for MCF-7 cell line using Cytotoxicity LDH Test (Roche, Poland).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!